{"id":113731,"date":"2025-08-27T12:34:09","date_gmt":"2025-08-27T12:34:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/113731\/"},"modified":"2025-08-27T12:34:09","modified_gmt":"2025-08-27T12:34:09","slug":"opus-genetics-inherited-retinal-disease-programs-featured","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/113731\/","title":{"rendered":"Opus Genetics Inherited Retinal Disease Programs Featured"},"content":{"rendered":"<p align=\"left\">RESEARCH TRIANGLE PARK, N.C., Aug.  27, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zvYwXKYKQzRZbi8Y7gTgCg75eeEHE2E2rWAOj-PUVs1F60uTLYTY_7gv-QjpXSLqegYUKUh3u9vDk6CHZBYbbkk_sxMCzUJvT-6FdE_WDvY=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Opus Genetics, Inc.\">Opus Genetics, Inc.<\/a> (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present on its IRD gene therapy programs at the following scientific conferences in September 2025.<\/p>\n<p>Presentation Details:<\/p>\n<p>Ophthalmology Futures Forum (Retina Forum)<\/p>\n<p style=\"padding-left:30px;\">Title: Gene &amp; Cell Therapies for Rare &amp; Common Retinal Diseases: Hype Vs Progress<\/p>\n<p>            Date\/Time: September 3, 2025, 12:20 pmPresenter: Sally Tucker, Ph.D., Senior Vice President Clinical DevelopmentFormat: Panel DiscussionLocation: Paris, France            <\/p>\n<p style=\"padding-left:30px;\">Opus Genetics Corporate Presentation<\/p>\n<p>            Date\/Time: September 3, 2025, 5:00 pmPresenter: Sally Tucker, Ph.D., Senior Vice President Clinical DevelopmentLocation: Paris, France             <\/p>\n<p>RD 2025 &#8211; International Symposium on Retinal Degeneration<\/p>\n<p style=\"padding-left:30px;\">Title: One-year results from a Phase I\/II study of OPGx-LCA5 subretinal gene therapy for the treatment of inherited retinal degeneration due to biallelic mutations in the LCA5 gene<\/p>\n<p>            Date: September 15, 2025Presenter: Ash Jayagopal, Ph.D., Chief Scientific &amp; Development OfficerLocation: Prague, Czech Republic            <\/p>\n<p>LSX World Congress<\/p>\n<p style=\"padding-left:30px;\">Title: The Equation for Maturation: Biotech Requirements to Achieve Scale<\/p>\n<p>            Date\/Time: September 17, 2025, 12:40 pmPresenter: Ben Yerxa, Ph.D., PresidentFormat: Panel DiscussionLocation: Boston, MA            <\/p>\n<p>About Opus Genetics<\/p>\n<p>Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company\u2019s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1\/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7tgj4I-QhcpSXA_tw_gbSIJ6oKvrSyNa9Kwat8ZyvLppWIwnarGXoDyL4HZKVyHCrAIDY41GULiU1Ldy4Us6jIdLzoofwMdJ4uE1msDOLiU=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.opusgtx.com\">www.opusgtx.com<\/a>.<\/p>\n<p>Contacts:<\/p>\n<p>Investors<br \/>Jenny Kobin<br \/>Remy Bernarda<br \/>IR Advisory Solutions<br \/>ir@opusgtx.com<\/p>\n<p>Media<br \/>Kimberly Ha<br \/>KKH Advisors<br \/>917-291-5744<br \/>kimberly.ha@kkhadvisors.com<\/p>\n<p>Source: Opus Genetics, Inc.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/08\/1756298049_70_Opus-Genetics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) &#8212; Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company&hellip;\n","protected":false},"author":2,"featured_media":31186,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,851,26148,26149,79],"class_list":["post-113731","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-inc","tag-nasdaqird","tag-opus-genetics","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/113731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=113731"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/113731\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/31186"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=113731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=113731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=113731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}